Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 7:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 42 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

NCT03524118
Conditions
Respiratory Tract Infection, Respiratory Syncytial Virus
Interventions
Clesrovimab, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Weeks to 8 Months
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
17
States / cities
Aurora, Colorado • Homestead, Florida • Miami, Florida + 14 more
Conditions
Bronchopulmonary Dysplasia
Interventions
Minimally invasive surfactant therapy, Continuation on CPAP
Device · Other
Lead sponsor
Menzies Institute for Medical Research
Other
Eligibility
1 Minute to 6 Hours
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
5
States / cities
New Haven, Connecticut • Honolulu, Hawaii • Evanston, Illinois + 2 more
Conditions
Respiratory Distress Syndrome, Pre-term Infants
Interventions
APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system), Control
Combination Product · Other
Lead sponsor
Aerogen Pharma Limited
Industry
Eligibility
1 Hour to 24 Hours
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Little Rock, Arkansas • La Jolla, California • Jacksonville, Florida + 9 more
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
CHF5633, Poractant alfa
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
1 Hour to 24 Hours
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Orange, California + 20 more
Conditions
Respiratory Syncytial Virus Infections
Interventions
MEDI8897, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 1 Year
Enrollment
3,012 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
66
States / cities
Birmingham, Alabama • Fort Defiance, Arizona • Fayetteville, Arkansas + 59 more
Conditions
Premature Birth of Newborn
Interventions
Kangaroo Care
Other
Lead sponsor
Case Western Reserve University
Other
Eligibility
7 Days to 37 Weeks
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Extended CPAP on Bronchopulmonary Dysplasia

NCT05547139
Conditions
Bronchopulmonary Dysplasia, Prematurity
Interventions
Protocolized weaning of respiratory support
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
22 Weeks to 30 Weeks
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Newark, Delaware
Conditions
Infant, Premature
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
Up to 1 Week
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

NCT01030575
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions
Inositol lower volume, Inositol mid-level volume, Inositol high volume, Placebo low volume
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
12 Hours to 72 Hours
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
17
States / cities
Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more
Conditions
BPD - Bronchopulmonary Dysplasia, Apnea of Prematurity, Hemodynamic Instability, Intubation
Interventions
Caffeine Citrate, Placebo (Normal Saline)
Drug
Lead sponsor
Jennifer Shepherd
Other
Eligibility
Up to 1 Day
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Los Angeles, California
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

NCT04767373
Conditions
Respiratory Syncytial Virus Infection
Interventions
Clesrovimab, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Up to 1 Year
Enrollment
3,632 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
51
States / cities
Dothan, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 45 more
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Betamethasone
Drug
Lead sponsor
Emory University
Other
Eligibility
Female only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Respiratory Syncytial Virus
Interventions
Placebo, MEDI8897 10 mg, MEDI8897 25 mg, MEDI8897 50 mg
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
Up to 12 Months
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
7
States / cities
Anaheim, California • Ontario, California • Syracuse, New York + 4 more
Conditions
Bronchopulmonary Dysplasia
Interventions
Gastric Feeds, Jejunal Feeds
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
0 Hours to 1 Year
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Respiratory Syncytial Virus Infections
Interventions
Suptavumab 30 mg/kg, Placebo Matched to Suptavumab, Suptavumab 30 mg/kg- 1 Dose, Suptavumab 30 mg/kg - 2 Doses
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
Up to 6 Months
Enrollment
1,177 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
107
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 104 more
Conditions
Infant,Premature
Interventions
Cardiorespiratory monitoring
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 98 Days
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Transient Tachypnea
Interventions
Prophylactic CPAP Administration
Other
Lead sponsor
New York Hospital Queens
Other
Eligibility
2 Minutes to 30 Minutes
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Flushing, New York
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Endotracheal tube insertion, Laryngeal mask airway insertion
Device
Lead sponsor
Albany Medical College
Other
Eligibility
4 Hours to 48 Hours
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Albany, New York
Conditions
BPD - Bronchopulmonary Dysplasia
Interventions
NAVA technology to synchronize NIPPV
Device
Lead sponsor
New York Medical College
Other
Eligibility
24 Weeks to 30 Weeks
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Valhalla, New York
Conditions
Apnea of Prematurity
Interventions
Caffeine Citrate, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
29 Weeks to 33 Weeks
Enrollment
827 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 12 more
Conditions
Infant,Premature
Interventions
Cardiorespiratory monitoring
Diagnostic Test
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 15 Days
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Patent Ductus Arteriosus, Preterm Infant, Bronchopulmonary Dysplasia
Interventions
Ibuprofen and acetaminophen, Ibuprofen and placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
5 Days to 21 Days
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Mobile, Alabama
Conditions
Ventilator-Induced Lung Injury, Respiratory Distress Syndrome, Bronchopulmonary Dysplasia, Preterm Infant
Interventions
Mid frequency ventilation, Standard frequency ventilation
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
1 Day to 3 Days
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Mobile, Alabama
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Fluid Management Intervention
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
Up to 12 Hours
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
New York, New York • Lawton, Oklahoma